MARY OGUNLOWO-OMOBHUDE: Open Payments
NPI 1508324971 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,801 in 83 payments from 14 companies in 2025. Trend: 2023 $393 · 2024 $2,445 · 2025 $1,801
Food & beverage: $1,700Education: $101
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 11 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $252 |
| ABBVIE INC. | 11 | $235 |
| Teva Pharmaceuticals USA, Inc. | 6 | $183 |
| Neurocrine BioSciences, Inc. | 7 | $157 |
| Alkermes, Inc. | 9 | $142 |
| Lundbeck LLC | 5 | $108 |
| Indivior Inc. | 3 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
Products named: COBENFY, CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, REXULTI, SUBLOCADE, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
